Insmed Inc (INSM)vsRapport Therapeutics, Inc. Common Stock (RAPP)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
RAPP
Rapport Therapeutics, Inc. Common Stock
$28.88
+2.23%
HEALTHCARE · Cap: $1.38B
Smart Verdict
WallStSmart Research — data-driven comparison
RAPP leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
RAPP
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : RAPP
The strongest argument for RAPP centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : RAPP
The primary concerns for RAPP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while RAPP is a value play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
RAPP generates stronger free cash flow (-25M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Rapport Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Rapport Therapeutics, Inc. is a cutting-edge biotechnology firm specializing in the development of innovative therapeutics aimed at addressing neurodegenerative disorders, with a particular focus on Alzheimer's disease and related cognitive impairments. The company leverages its proprietary drug candidates and advanced technology platforms to drive robust scientific research and clinical validation, positioning itself as a leader in neuroscience innovation. By targeting significant unmet medical needs, Rapport is poised to make meaningful contributions to the evolving biotech landscape, offering potential solutions for patients suffering from debilitating cognitive conditions.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?